GPCR today
$20.95-$0.78 (-3.59%)close Nov 11, 2026Trend
DailyDowntrend (confirmed)
4 hourStrong Bearish
1 hourStrong Bullish
15 minSymmetric Triangle
5 minStrong Bearish
Daily trend turns up above $22.36
Key levels
Resistance$25.59
Resistance$22.72
Support$20.50
Support$18.70
Latest news & SEC filings
DealStructure Therapeutics partners with Unlearn on AI digital twins for obesity research
EarningsStructure Therapeutics Posts Q3 2026 Results, Business Update
EarningsStructure Therapeutics Posts Wider Third-Quarter Loss of $0.66 Per Share
SEC FilingStructure Therapeutics Inc. filed a report on a major company event (Form 8-K)
All GPCR news →About Structure Therapeutics
Structure Therapeutics is a clinical-stage biopharmaceutical company that develops oral small molecule medicines for chronic diseases. Its pipeline targets G-protein coupled receptors, with lead programs in obesity and related metabolic conditions, including a GLP-1 receptor agonist and amylin receptor agonists. The company operates in the United States and conducts clinical studies internationally.
Based on the company's 10-K filed Feb 26, 2026.
Nasdaq · Healthcare
Structure Therapeutics Inc. (GPCR)
What Is the Price Target for GPCR?
SEPT Low Target
$70.00
SEPT Mid Target
$101.00
SEPT High Target
$110.00
Analyst Consensus
$101.00
Is GPCR a Buy or Sell Right Now?
Thesis
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for GPCR.
Start Free Trial →Is GPCR Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
Analyst Consensus
Fair Value
$101.00
12
Moat Score
NONE
2/9
Piotroski Score
30.5
Altman Z-Score
What Is Smart Money Doing with GPCR?
Insider Signal
NEUTRAL
0 buys / 0 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
MEDIUM
Signal: NEUTRAL
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Coll Crespo Blas | officer | Sale | 12,024 | - | Sep 21, 2026 |
| Coll Crespo Blas | officer | Sale | 10,626 | $124K | Sep 18, 2026 |
| Lin Xichen | officer | Buy | 17,817 | $6K | Sep 1, 2026 |
| Lin Xichen | officer | Sale | 17,817 | - | Sep 1, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →GPCR Growth Story
Revenue YoY
N/A%
3yr Revenue CAGR
N/A%
EPS Growth YoY
-2.56%
FCF Growth YoY
-91.5%
Revenue Trend
UNKNOWN
Dark Pool Trades for GPCR
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for GPCR, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 21:00:26 | $20.95 | 1,319 | $$28K | SELL |
| 21:00:26 | $20.95 | 3,398 | $$71K | SELL |
| 21:00:26 | $20.95 | 6,567 | $$138K | SELL |
| 20:58:56 | $20.96 | 2,600 | $$55K | BUY |
| 20:58:00 | $21.00 | 5,900 | $$124K | MIDPOINT |
5 dark pool trades shown · $$415K preview volume
Real-time institutional flow, block trades, and net positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for Structure Therapeutics Inc. (GPCR) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →GPCR — frequently asked questions
What is GPCR stock price today?
Structure Therapeutics Inc. (GPCR) is at $20.95, down 3.59% (-$0.78) at the Nov 11, 2026 close.
Why is GPCR stock moving today?
Latest GPCR news — Nov 12, 2026: Structure Therapeutics partners with Unlearn on AI digital twins for obesity research · Nov 9, 2026: Structure Therapeutics Posts Q3 2026 Results, Business Update
What is the GPCR price target?
The average analyst price target for GPCR is $101.00, ranging from $70 to $110, based on 5 analysts.
What do analysts rate GPCR?
Analyst ratings for GPCR: 15 Buy, 1 Hold, 0 Sell — consensus Strong Buy.
Did GPCR beat earnings?
GPCR last reported on Aug 6, 2026: EPS -$0.49 vs -$0.39 expected — a miss of 25.6%.
Does GPCR pay a dividend?
GPCR does not currently pay a dividend.
What are GPCR support and resistance levels?
Support: $20.50, $18.70, $15.80. Resistance: $22.72, $25.59, $28.12.
What are insiders doing with GPCR?
Insider activity: NEUTRAL, 0 buys and 0 sells in the last 90 days.
What is the latest news on GPCR?
Nov 12, 2026: Structure Therapeutics partners with Unlearn on AI digital twins for obesity research · Nov 9, 2026: Structure Therapeutics Posts Q3 2026 Results, Business Update · Nov 9, 2026: Structure Therapeutics Posts Wider Third-Quarter Loss of $0.66 Per Share